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538Objective: Stage I or II small cell lung cancer is rare. We evaluated the contemporary incidence of early-stage
small cell lung cancer and defined its optimal local therapy.
Methods:We analyzed the incidence, treatment patterns, and outcomes of 2214 patients with early-stage small
cell lung cancer (1690 with stage I and 524 with stage II) identified from the Surveillance, Epidemiology, and
End Results database from 1988 to 2005.
Results: Early-stage small cell lung cancer constituted a stable proportion of all small cell lung cancers (3%–
5%), lung cancers (0.10%–0.17%), and stage I lung cancers (1%–1.5%) until 2003 but, by 2005, increased
significantly to 7%, 0.29%, and 2.2%, respectively (P<.0001). Surgery for early-stage small cell lung cancer
peaked at 47% in 1990 but declined to 16% by 2005. Patients treated with lobectomy or greater resections (lobe)
without radiotherapy had longer median survival (50 months) than those treated with sublobar resections (sub-
lobe) without radiotherapy (30 months, P ¼ .006) or those treated with radiotherapy alone (20 months,
P<.0001). Patients undergoing sublobe without radiotherapy also demonstrated superior survival than patients
receiving radiotherapy alone (P ¼ .002). The use or omission of radiotherapy made no difference after limited
resection (30 vs 28 months, P ¼ .6). Multivariable analysis found survival independently related to age, year of
diagnosis, tumor size, stage, and treatment (lobe vs sublobe vs radiotherapy alone).
Conclusions: Surgery is an underused modality in the management of early-stage small cell lung cancer.
Lobectomy provides optimal local control and leads to superior survival. Although sublobar resection proved
inferior to lobectomy, it conferred a survival advantage superior to radiotherapy alone. The addition of radiother-
apy to resection provided no additional benefit. (J Thorac Cardiovasc Surg 2011;142:538-46)Before the 1970s, surgical resection was often used to treat
localized early-stage small cell lung cancer (SCLC).1 How-
ever, in 1973, the Medical Research Council published the
only prospective, randomized trial comparing resection
with radiotherapy (RT).2 This demonstrated that definitive
RT yielded a higher survival than surgery and thus estab-
lished RT as the procedure of choice. However, this trial
was conducted before modern pathologic assessment,3 the
establishment of platinum-based chemotherapy,4 and the
development of modern surgical and radiotherapeutic tech-
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The Journal of Thoracic and Cardiovascular SurgCancer Network guidelines recommend either lobectomy
(preferred) and mediastinal node sampling or dissection,
or concurrent chemotherapy and RT for all patients who
have clinical T1–2N0 presentations of SCLC with negative
mediastinoscopy or mediastinal staging.5 This guideline is
considered to be in category 2A, meaning that it is based
on lower-level evidence, but there is uniform consensus
among the guideline participants.
Because early-stage SCLC is a rare presentation of lung
cancer, prospective, randomized trials comparing local
treatment modalities are unlikely to be performed. There-
fore, the main purpose of our retrospective investigation
was to compare results with surgery alone, RT alone, and
combined surgery and RTon survival. In addition, we inves-
tigated the frequency of early-stage SCLC as a percentage
of all SCLCs, all lung cancers, and all stage I lung cancers.
Finally, because some physicians are treating patients with
unbiopsied but suspicious lung masses with stereotactic
body RT, we compared the presenting characteristics of pa-
tients with resected stage I SCLC with those of resected
stage I non–small cell lung cancer (NSCLC).6-9PATIENTS AND METHODS
Data were obtained from the Surveillance, Epidemiology, and End Re-
sults (SEER) program of the US National Cancer Institute. The SEER-17
database includes patients with diagnoses made between 1988 and 2005,ery c September 2011
Abbreviations and Acronyms
CI ¼ confidence interval
HR ¼ hazard ratio
LCSS ¼ lung cancer-specific survival
NOS ¼ not otherwise specified
NSCLC ¼ non–small cell lung cancer
RT ¼ radiotherapy
SCLC ¼ small cell lung cancer
SEER ¼ Surveillance, Epidemiology, and End
Results
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Sand is derived from a set of geographically defined, population-based can-
cer registries operated under direct contract with the National Cancer Insti-
tute by local nonprofit organizations in Connecticut, Iowa, Hawaii, New
Mexico, Utah, Atlanta, Detroit, Los Angeles, San Francisco-Oakland,
San Jose-Monterey, Seattle-Puget Sound, Rural Georgia, Kentucky, Loui-
siana, and New Jersey, and among Arizona Indians and Alaskan Native
populations.10 The case ascertainment rate from the SEER registries has
been reported to be 97.5% and is thought to be generally representative
of the entire American population.11 Data were accessed on February 3,
2009. Because we used existing data that did not identify individual
subjects, informed consent by the study participants was not necessary.
Patients with less than 3 months of follow-up were excluded.
Patients with a stage I or II SCLC diagnosis, defined according to the
American Joint Committee on Cancer,12 were selected for this analysis.
Histologic types identified as SCLC including combined small cell and
fusiform cell carcinomas were used for analysis. The following histologic
types were defined as NSCLC: NSCLC not otherwise specified (NOS,
which included undifferentiated carcinoma NOS and anaplastic carcinoma
NOS); large cell carcinoma (large cell neuroendocrine carcinoma, large cell
carcinoma with rhabdoid phenotype, lymphoepithelioma-like carcinoma,
basaloid carcinoma, and clear cell carcinoma); adenocarcinoma (including
acinar cell carcinoma, mixed subtype adenocarcinoma, alveolar adenocar-
cinoma, bronchioloalveolar carcinoma, non-mucinous bronchioloalveolar
carcinoma, mucinous bronchioloalveolar carcinoma, mixed mucinous and
non-mucinous bronchioloalveolar carcinoma, clear cell adenocarcinoma,
mucinous cystadenocarcinoma, mucinous or colloid adenocarcinoma,
mucin-producing adenocarcinoma, papillary adenocarcinoma, signet ring
adenocarcinoma, solid adenocarcinoma, well-differentiated fetal adenocar-
cinoma); adenosquamous carcinoma; and squamous cell carcinoma (basa-
loid squamous cell carcinoma, papillary squamous cell carcinoma, clear cell
squamous cell carcinoma, keratinizing squamous cell carcinoma, large cell
non–keratinizing squamous cell carcinoma, and small cell non–keratinizing
squamous cell carcinoma). Surgery was characterized as lobe (lobectomy,
bilobectomy, pneumonectomy, or extended pneumonectomy) or sublobe
(wedge or segmental resection).
To compare presenting characteristics of stage I SCLC and stage I
NSCLC, data for both histologic subtypes were obtained for patients
who underwent a definitive surgical procedure and were analyzed using
chi-square andWilcoxon rank-sum tests. Characteristics analyzed included
age, sex, race (white, black, other), tumor location (left lower, left upper,
right lower, right middle, and right upper lobes, and mainstem bronchus
locations), and tumor size.
Unadjusted, stratified analyses were performed to compare survival for
sublobe without RT versus lobe without RT, sublobe without RT versus RT
only, lobe without RT versus RT only, sublobe without RT versus sublobe
with RT, and lobe without RT versus sublobe with RT. The log-rank test
was used to test for differences in survival among the various treatments.13
All survival curves were generated using the Kaplan–Meier method.14The Journal of Thoracic and CaTo assess the effect of treatment on survival while controlling for other
factors, a multivariable proportional hazards model was performed. Treat-
ment was analyzed as a categoric variable, with categories representing the
various combinations of surgery with and without RT (sublobe without RT,
sublobe with RT, lobe without RT, lobe with RT), in addition to a separate
category for RT only. Patients without surgery or radiation were excluded
from the analysis. The following covariates were also included: year of di-
agnosis, patient age, race, gender, tumor stage, tumor location, nodes ex-
amined (none, 1–5, 6, unknown), and size.RESULTS
There were 2214 patients identified with early-stage
SCLC and more than 3 months of follow-up. The median
survival time was 20 months for the entire group. The dis-
tribution of patient and histopathologic characteristics by
treatment are described in Table 1. The percentage of stage
I and II SCLC among all SCLCs (Figure 1, A) remained
relatively stable between 1988 and 2003 (range, 3.00%–
4.96%), but increased dramatically in 2004 and 2005
(6.86% and 7.48%, P<.0001). Likewise, the percentage
of stage I and II SCLCs among all lung cancers (Figure 1,
A) and the percentage of stage I SCLCs among all stage I
lung cancers (Figure 1, B) remained stable during the years
1988 to 2003 (ranges, 0.10%–0.17% and 0.73%–1.51%,
respectively), but also increased greatly during the years
2004 and 2005 (0.28% and 0.29%, and 2.11% and
2.22%, respectively; P<.0001).
The median survival time for patients with stage I SCLC
treated with lobectomy without RT (50 months) was signif-
icantly greater than that for patients treated with sublobar
resection without RT (30 months, P ¼ .006) and those
treated with RT alone (20 months, P<.0001). The median
overall survival time was also significantly longer for
patients treated by sublobar resection without RT than for
patients who received RT alone (P ¼ .002). The 2-, 3-,
and 5-year actuarial overall survivals for patients undergo-
ing lobectomy without RTwere 65.2%, 58.6%, and 47.4%,
respectively, compared with 62.5%, 41.7%, and 28.5%, re-
spectively, for those undergoing sublobar resection without
RT and 39.6%, 28.3%, and 17.2%, respectively, for pa-
tients treated by RT alone (Figure 2, A). Likewise, patients
treated by lobectomy without RT had a greater median lung
cancer-specific survival (LCSS) (89 months) than those
treated with sublobar resection without RT (35 months,
P ¼ .037) or those treated with RT alone (24 months,
P<.0001), as shown in Figure 2, B.
When lobectomy or greater was performed, the use of ad-
juvant RTwas associated with a shorter but not significantly
different median survival time (50 vs 37 months, P¼ .201).
The overall survival and LCSS also did not differ for these
groups (Figure 3, A, B). No difference in the median overall
survival time was found with the use of adjuvant RT when
sublobar resection was performed (30 vs 28 months,
P ¼ .585) or in overall survival of LCSS rates (Figure 3,
C, D).rdiovascular Surgery c Volume 142, Number 3 539
TABLE 1. Patient-related and histopathologic factors
All patients
(n ¼ 2214)
No treatment*
(n ¼ 558)
Surgery only
(n ¼ 436)
Radiation only
(n ¼ 936)
Surgery and radiation
(n ¼ 148)
Gender
Female 1144 (52) 293 (53) 216 (50) 490 (52) 74 (50)
Male 1070 (48) 265 (47) 220 (50) 446 (48) 74 (50)
Age
20–49 y 100 (5) 12 (2) 15 (3) 55 (6) 11 (7)
50–59 y 324 (15) 63 (11) 60 (14) 150 (16) 29 (20)
60–69 y 693 (31) 146 (26) 147 (34) 296 (32) 58 (39)
70–79 y 861 (39) 256 (46) 184 (42) 324 (35) 48 (32)
80+ y 236 (11) 81 (15) 30 (7) 111 (12) 2 (1)
Race
White 1910 (86) 465 (83) 395 (91) 798 (85) 128 (87)
Black 190 (9) 66 (12) 25 (6) 80 (9) 10 (7)
Other 112 (5) 27 (5) 16 (4) 57 (6) 9 (6)
Stage
I 1690 (76) 445 (80) 361 (83) 692 (74) 87 (59)
II 524 (24) 113 (20) 75 (17) 244 (26) 61 (41)
Grade
I–II 31 (1) 6 (1) 16 (4) 4 (0.4) 5 (3)
III 252 (11) 45 (8) 94 (22) 69 (7) 32 (22)
IV 939 (42) 236 (42) 187 (43) 398 (43) 58 (39)
Unknown 992 (45) 271 (49) 139 (32) 465 (50) 53 (36)
Location
Lower left 344 (16) 90 (17) 57 (13) 136 (15) 37 (26)
Upper left 573 (27) 136 (26) 127 (30) 240 (27) 36 (25)
Middle bronchus 137 (7) 41 (8) 0 (0) 83 (9) 2 (1)
Lower right 325 (15) 77 (15) 81 (19) 139 (16) 13 (9)
Middle right 132 (6) 31 (6) 27 (6) 57 (6) 11 (8)
Upper right 593 (28) 145 (28) 137 (32) 232 (26) 46 (32)
No. of nodes examined
None 1641 (74) 531 (95) 90 (21) 901 (96) 31 (21)
1–5 242 (11) 10 (2) 134 (31) 17 (2) 57 (39)
6 + 199 (9) 6 (1) 144 (33) 2 (0.2) 37 (25)
Unknown 132 (6) 11 (2) 68 (16) 16 (2) 23 (16)
No. of positive nodes
0 409 (19) 17 (3) 277 (65) 21 (2) 58 (41)
1+ 139 (6) 9 (2) 61 (14) 9 (1) 52 (37)
None examined 1641 (75) 531 (95) 90 (21) 901 (97) 31 (22)
Tumor size 30.0 (0–210) 30.0 (0–210) 23.0 (3–110) 35.0 (0–150) 21.5 (4–130)
Type of surgical resection
Less than lobectomy 167 (8) 117 (27) 46 (31)
Lobectomy/bilobectomy 412 (19) 304 (70) 92 (62)
Pneumonectomy 28 (1) 15 (3) 10 (7)
*Includes tumor that underwent biopsies, laser ablation, or local cautery.
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SResults of the multivariable proportional hazards model
are shown in Table 2. Characteristics significantly associ-
ated with overall survival were year of diagnosis (hazard ra-
tio [HR]¼ 0.98; 95% confidence interval [CI], 0.97–0.998;
P¼ .029), age (HR¼ 1.19; 95% CI, 1.14– 1.24; P<.0001),
stage II (HR ¼ 1.48; 95% CI, 1.26–1.74; P<.0001), tumor
size (HR¼ 1.01; 95% CI, 1.001–1.01; P¼ .014), lobe with-
out RT versus RT only (HR ¼ 0.56; 95% CI, 0.41–0.76;
P<.001), and lobe without RT versus sublobe without RT
(HR ¼ 0.73; 95% CI, 0.53–0.999; P ¼ .049).540 The Journal of Thoracic and Cardiovascular SurgTrends in the use of the various local therapeutic options
can be seen in Figure 4. The use of RTonly was at its lowest,
18%, in 1990, but increased to 46% of all treatments in
1991 and subsequently ranged from 35.7% to 50.0%. Dur-
ing the new century, the use of RT only remained at 44.2%
to 50.0%. No local treatment was at its lowest use in 1991 at
16.0%, but since 1990 its use has fluctuated from 19.8% to
34.3%. The use of surgery only peaked in 1990 at 47.4% of
all local treatments, but its use decreased greatly during the
1990s (range, 18.2%–29.7%) and in the new century (range,ery c September 2011
FIGURE 1. A, Frequency of stage I/II SCLC as a percentage of all SCLCs
and as a percentage of all lung cancers (NSCLC and SCLC). B, Frequency
of stage I SCLC as a percentage of all stage I lung cancers. NSCLC,
Non–small cell lung cancer; SCLC, small cell lung cancer.
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FIGURE 2. A, Actuarial survivals for patients treated with RT only,
sublobar resection without RT, and lobectomy without RT. B, Actuarial
LCSS for patients treated with RT only, sublobar resection without RT,
and lobectomy without RT. LCS, Lung cancer-specific; RT, radiotherapy.
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relatively uncommon and ranged from 1.4% to 13.6% of
all local treatment options, peaking in 1999 at 13.6%.
When patients treated with surgical resection for stage I
SCLC were compared with those identified in SEER as
having surgical therapy for stage I NSCLC, there were no
differences in patient age, gender, race, or tumor location
(data not shown). SCLC tumors were numerically but not
statistically smaller in size.
DISCUSSION
The National Comprehensive Cancer Network Guide-
lines currently recommend either surgery (lobectomy pref-
erable) or chemotherapy and concurrent RT for patients
with good-performance status with clinical T1–2 N0
SCLCs. However, because of the rarity of this early presen-
tation, there are scant data on which local modality to con-
sider and even the type of surgical resection (ie, lobectomyThe Journal of Thoracic and Cavs sublobar resection). Although early-stage SCLC remains
rare, our investigation has shown that this presentation sig-
nificantly increased during 2004 and 2005 and now com-
prises more than 7% of all small cell carcinomas.
Moreover, stage I SCLC now constitutes more than 2%
of all stage I lung cancers. To the best of our knowledge,
there are no prospective or retrospective data comparing
outcomes of different local treatment modalities to help
guide therapeutic decisions. As shown in a previous pro-
spective, randomized trial, which investigated the benefit
of surgical resection in addition to chemotherapy and
RT,15 our analysis similarly revealed that there was no
survival benefit for patients to receive 2 local treatment
modalities (radiation in addition to surgical resection).
Patients who were treated with RT as their sole local
treatment modality were likely understaged. Ninety-seven
percent of patients received only clinical staging and did
not have any lymph nodes examined, compared with 21%rdiovascular Surgery c Volume 142, Number 3 541
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FIGURE 3. A, Actuarial survivals for patients treated with lobectomywith and without RT. B, Actuarial LCSS for patients treated with lobectomywith and
without RT. C, Actuarial survivals for patients treated with sublobar resection with and without RT. D, Actuarial LCSS for patients treated with sublobar
resection with and without RT. LCS, Lung cancer-specific; RT, radiotherapy.
General Thoracic Surgery Varlotto et al
G
T
Sof patients treated with surgery only and 22% of patients
receiving both surgery and RT. Because the routine use of
positron emission tomography as a staging tool was only
practiced in the most recent 5-year time frame of this
17-year retrospective analysis, a survival comparison of
resection versus RT alone must be interpreted with extreme
caution. Such a staging bias was emphasized by the
International Association for the Study of Lung Cancer
International Staging Committee in their recent report
documenting a 20% to 25% rate of upstaging when patients
with clinically staged SCLC underwent resection with
nodal evaluation.16 In view of these considerations, a multi-
variable analysis (which controlled for the number of lymph
nodes examined) revealed that lobectomy without RT was
associated with a significant survival benefit compared
with RT alone (P ¼ .0002, HR 0.559).
Lobectomy is the standard of care for resection of patho-
logic stage I NSCLC, providing superior survival and
a lower risk of local recurrence than segmentectomy or542 The Journal of Thoracic and Cardiovascular Surgwedge resection.17 Likewise, although retrospectively, our
analysis revealed lobectomy (or greater if indicated) led
to superior overall and cancer-specific survival and remains
the surgical procedure of choice over sublobar resections
for node-negative SCLC.
Despite the compelling argument in favor of surgery for
stage I SCLC, 42% of patients in this retrospective analysis
received RT as their sole local treatment modality. It is
unfortunate that SEER-17 does not contain information
on important radiation parameters, suchasfield size, radiation
dose, intent of treatment, 3-dimensional versus 2-dimensional
treatment planning, and fractionation schedule. With more
advanced small cell presentations, hyperfractionated, acceler-
ated treatment results in superior response rates and survival
than does conventional fractionation.18 Whether this is true
for early-stage SCLC is not currently known.
The multivariable analysis also demonstrated that
survival depended on year of diagnosis, patient age, stage,
and tumor size. The recent International Association forery c September 2011
TABLE 2. Multivariable analysis for S with radiotherapy ± surgery as
covariate (excluding patients treated with neither surgery nor
radiotherapy)
Hazard ratio (95% CI) P value
Year of diagnosis 0.982 (0.966–0.998) .029
Age 1.189 (1.144–1.236) <.0001
Race .231
White Reference
Black 1.249 (0.968–1.612) .088
Other 1.002 (0.748–1.343) .988
Male 1.040 (0.907–1.193) .576
Tumor location .067
Left lower 0.970 (0.787–1.195) .773
Left upper 0.810 (0.676–0.970) .022
Mainstem bronchus 1.020 (0.735–1.414) .907
Right lower 0.759 (0.614–0.940) .011
Right middle 0.909 (0.678–1.218) .522
Right upper Reference
Stage II 1.479 (1.259–1.737) <.0001
Nodes examined .634
0 Reference
1–5 0.912 (0.686–1.213) .527
6 0.844 (0.597–1.193) .336
Unknown 0.796 (0.557–1.140) .213
Tumor size 1.005 (1.001–1.008) .014
Treatment .009
RT only Reference
L- without RT 0.771 (0.582–1.022) .071
L- with RT 0.745 (0.490–1.133) .168
Lþwithout RT 0.559 (0.410–0.763) <.001
Lþwith RT 0.683 (0.466–1.002) .051
CI, Confidence interval; RT, radiotherapy.
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survival was directly correlated to both T and N descrip-
tors.19 Lally and colleagues20 found older age, male gender,
era of diagnosis, and African American race were indepen-
dent predictors of hazard for mortality when limited-stage
SCLC cases from SEER were reviewed. These cases in-
cluded N0, N1, and N2 disease, and the analysis did not
consider surgery as a therapeutic modality.20 Schreiber
and colleagues21 recently used SEER to identify 14,179 pa-
tients with limited-stage SCLC, of whom only 6.1% under-
went surgery. These investigators also demonstrated
advancing age and male gender as risk factors for poor sur-
vival. They did find a statistical benefit to postoperative RT
in patients with N2 disease (P¼ .011).21 We are unaware of
any studies revealing the prognostic significance of year of
diagnosis in surgically resected SCLC. Patient age has been
demonstrated to be prognostic of survival in NSCLC.22,23
Improved survival could be related to year of diagnosis
because of increased incidence of incidentally detected
cancers,24 improvement in radiation techniques,18,25 and
better staging.26 It should be noted that during the years
of this investigation, there was no survival improvementThe Journal of Thoracic and Caresulting from using chemotherapy in patients with
SCLC.27,28
There is a recent trend by certain physicians to treat
growing or positron emission tomography-positive nodules
without biopsy using stereotactic body RT6-9 under the as-
sumption that these metabolically active nodules represent
NSCLC. We hoped that we could differentiate early-stage
SCLC from early-stage NSCLC on the basis of their pre-
senting characteristics. However, other than early-stage
SCLCs being associated with slightly smaller tumor size
on presentation, surgically resected stage I SCLC did not
differ from NSCLC with regard to patient characteristics
or tumor location. Because of the differences in treatment
paradigms for stage I SCLCs, which all require chemother-
apy and NSCLCs, which do not, we urge a biopsy of such
nodules be performed whenever possible.
In addition to limitations regarding RT parameters, the
SEER-17 database also does not provide information on
performance status, weight loss, patient smoking status,
lymphatic or vascular invasion, completeness of resection,
lymph node level dissected, preoperative evaluation, receipt
of chemotherapy, type of chemotherapeutic agents, and
recurrence pattern. Therefore, the observed differences in
overall survival and LCSS for patients undergoing surgery
may have been due to selection factors (eg, patients with bet-
ter performance status preferentially undergoing resection).
Of note, during the years of our investigation, the use of
RT increased and the use of surgery decreased. This trend
began 2 years before publication of a meta-analysis con-
firming the role of RT in limited-stage disease,29 so the
reasons for it are not clear.
CONCLUSIONS
Anatomic lobectomy without the use of adjuvant RT
seems to be the optimal local therapy for patients withrdiovascular Surgery c Volume 142, Number 3 543
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G
T
Searly-stage SCLC. In the absence of mediastinal nodal ex-
tension or remote metastatic disease, the addition of adju-
vant RT after sublobar resection does not improve overall
or cancer-specific survival. RT should be considered for pa-
tients who are unfit for any surgical resection.
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Dr Jessica Donington (New York, NY). Thoracic surgery has
been discounted for the treatment of SCLC since the 1970s and
1980s because of some randomized trials that lumped all of the
limited disease together, probably inappropriately. I think the
nicework Eric Vallieres did as part of the International Association
for the Study of Lung Cancer Lung Cancer Staging Project showed
us that for patients with SCLC without metastatic disease, both the
T stage and the N stage carry significant prognostic and therapeutic
implications. I congratulate you on this excellent work. In looking
at that, do we have to look at this as a review of SEER data? I have
actually never performed a SEER review, so maybe you can edu-
cate me as to some of the things we can and can’t take out of this.
When we look at the way the patients were staged in this series,
I’m assuming that we have both clinical and pathologic stages
that we are comparing between the radiation and the surgery
groups. Correct?
Dr DeCamp. SEER reports the use of surgery and reports down
to the histology of lymph nodes that are sampled, so in the surgery
group, obviously there is more precise staging than in the patients
with no resection, so they may have only a biopsy, as you saw in
Tables 1 and 2.
Dr Donington. So it would be comparing apples and oranges in
terms of survival. I guess the samemay also be true in that we don’t
really know about intention to treat and the use of sublobar versus
lobectomy or greater in treatment. I’m assuming the sublobars in
this series were probably performed in patients who could not
tolerate a lobectomy, or we just don’t have any information?
Dr DeCamp. We have no knowledge of the surgeon’s intent.
When we looked at segmentectomy versus wedge resection, the re-
sults didn’t seem any different. Likewise, if we lumped lobectomy,
bilobectomy, and pneumonectomy together, if we tried to split out
pneumonectomy, there was no difference in the data, but obvi-
ously, because it’s retrospective, there is a possibility for selection
bias.ery c September 2011
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SDrDonington.What kind of information does SEER provide in
terms of knowing about the radiation given? I know it doesn’t give
specifics about field, intensity, and such. Was it all thoracic radia-
tion or was some of this percutaneous coronary intervention?
Dr DeCamp. No, this was all thoracic radiation.
Dr Donington. Do we know about how much prophylactic cra-
nial irradiation was given to these patients? We know that signif-
icantly affects survival in this population.
Dr DeCamp. No, we don’t.
Dr Donington.Your work actually coincides with several other
reviews of the SEER database looking at surgical resection for
SCLC. The 3 reviews, yours, one from Yale, and one from
SUNY Downstate, have similar take-home messages: There really
is an important role for surgery. Some of the take-home message
regarding the use of adjuvant RT, though, was different. Can you
address the fact that those 2 studies actually found no impact
from the use of adjuvant RT, or in the SUNY review, a similar
kind of pattern to what we see in NSCLC, where with increasing
nodal status, perhaps adjuvant radiation makes sense.
Dr DeCamp. The difference among the 3 SEER reviews is that
we restricted ourselves to early stage, not limited stage, as the
oncologists like to speak of it, but T1N0, T2N0, and N1 cases.
The SUNYDownstate review, which is primarily written by radio-
therapists, makes the analogy to the PORT meta-analysis in
NSCLC; in that analysis, there was a detriment when radiation
was used in stage I disease, although it included some old radiation
from the 1970s, which may have been more detrimental, no benefit
for stage II, but a small survival benefit in stage III disease. We
have no patients with stage III in our series, and we are doing
this from the perspective of surgeons and clinicians.
Dr Donington. Did you see any difference in survival with ra-
diation between those with stage I and those with stage II?
Dr DeCamp.No, we didn’t. It seems that the patients derive no
additional benefit from the addition of radiation after surgery. As
you see from the curves, the P values are between .2 and .5, so
they are statistically similar and clearly inferior to any of the sur-
gical arms, which was surgery alone.
Dr Donington. My last question is speculative in nature. Do
you have any insight as towhy we saw that fairly dramatic increase
in the cases of small cell in 2004 and 2005?
DrDeCamp. I found that kind of interesting in an era when half
the American smoking population quit smoking in the last 30
years. Sowe have fewer active smokers. Small cell tends to be a dis-
ease of active smokers. I think a lot of it has to do with the increas-
ing utility of computed tomography scanning and finding more
tumors earlier, and that may be a prediagnosis or an overdiagnosis
bias, but as we think about NSCLC and SCLC, people die of these
diseases; they don’t die with these diseases. So I have a hard time
accepting the overdiagnosis bias argument. I don’t know why
we’re seeing so many more small cell cases, but it was curious
and consistent in the last 4 or 5 years of this review.
Dr Donington. I think it makes your article ever more
important.
Dr Raja Flores (New York, NY). Mac, I commend you on doing
a great job with the limited data that are presented in SEER. I think
this does add support to thoracic surgeons performing surgical
resection for SCLC. I have a quick question. With these patients
who underwent surgery, do you have any idea of the number ofThe Journal of Thoracic and Capatients who underwent preoperative mediastinoscopy? Is that
recorded at all in the SEER database?
Dr DeCamp. No. You just get a report of lymph nodes. You
don’t get a report of how they were obtained. So you get medias-
tinal or hilar lymph nodes. We can assume the hilar nodes were not
at mediastinoscopy.
Dr Mark Iannettoni (Iowa City, Iowa). Mac, I enjoyed your
article. This is the third time we’ve heard that surgery has value
for SCLC. In 1985 John Meyer presented it. Tom Shields has pre-
sented it in the past. Why do you think we just haven’t gotten
through to people yet that this is a valuable entity?
Dr DeCamp. I can only speculate that there are not multidisci-
plinary teams evaluating patients, and if you don’t see them and
you’re not involved, you won’t be at the table making the treatment
decisions. The SUNY Downstate review, which was primarily
written by radiation oncologists, and the current article will bring
this more into the consciousness, and with more multidisciplinary
evaluations being performed around the country, we’ll be back at
the table.
Dr Iannettoni. I think that’s the point. We need to get out of the
operating room and get to some of these conferences.
Dr Joe Putnam (Nashville, Tenn). I enjoyed the article and was
curious if this may reflect a more nihilistic approach of other spe-
cialists, such as medical or radiation oncology. These specialists
see patients with more advanced stage SCLC and may be reluctant
to have smaller SCLCs treated with resection as an initial treat-
ment modality.
The question I have is about diagnosis. Were you able to deter-
mine the percentage of patients who had a diagnosis preopera-
tively versus postoperatively? Many of these patients may have
a diagnosis made as a consequence of operations for a solitary
pulmonary nodule.
Dr DeCamp. From the SEER data, I know of no way to
discriminate or answer that question specifically.
Dr Putnam. From your data, the change over time may have
resulted in the increased use of computed tomography and other
diagnostic studies, as well as more availability of preoperative nee-
dle diagnosis. In those patients who had a diagnosis of SCLCmade
with needle diagnosis, the surgeon may never see them, even if
they have limited and resectable disease. It may be helpful to
partner with our radiologists in addition to our medical oncologists
to understand that these patients can be seen by a surgeon and
effectively treated.
Dr Stephen Yang (Baltimore, Md). As a follow-up to this,
maybe we can have a take-home message from all these article.
I’ll sort of plug Malcolm Brock’s article from 1997 from our insti-
tution, in which he showed that with platinum-based therapy these
days, surgery plus chemotherapy affords a 75% 5-year survival for
stage I disease. The take-home message now: The patient comes
in, small cell, preoperative diagnosis. What do you tell the tumor
board? In the second scenario, as Bill alluded to, the patient has
a lobectomy for a solitary nodule, and it comes back a small
cell. What is the decision point after that?
Dr DeCamp. Thank you, Steve. I have to take my hat off to
Dave Sugarbaker if he’s in the audience because he taught me
that you evaluate a solitary pulmonary nodule, and if it is small
cell and the mediastinum is negative, take it out. You do the lobec-
tomy. Treat it like you do lung cancer. If this person clearly needsrdiovascular Surgery c Volume 142, Number 3 545
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Ssystemic therapy, you know, that’s the greatest risk. If I’ve done
a mediastinoscopy and lobectomy on the basis of what we learned
this morning or a goodmediastinal sampling or radical mediastinal
lymphadenectomy, as long as I’ve assessed the mediastinum, that
patient has had adequate local therapy, and the patient needs sys-
temic therapy and doesn’t benefit from radiation therapy.
Dr Yang. Just one more comment. We have put in an American
College of Surgeons Oncology Group protocol for small cell. I
hope it will be engaged in about 1 year. We are going to be looking
at this prospectively for patients who do have small cell. They do
receive chemotherapy postoperatively. But I think the more impor-
tant thing will be looking at the translational material, getting the
blood, sputum, and tumor sample so we can learn more about the
disease, which we haven’t had in the past.
DrRobert Cerfolio (Birmingham, Ala). So, Mac, I’m in the op-
erating room. I wedge it out. They call back with small cell. I take
all the N2 nodes and send those for frozen-section, and 2 of them
are positive, microscopic disease. Do I do a lobe or don’t I?
Dr DeCamp. I don’t think you need to do a lobe.546 The Journal of Thoracic and Cardiovascular SurgDr Jack Roth (Houston, Tex). It’s not unusual to see mixed his-
tologies with both small cell and non–small cell components.
Given the time frame of this study and the radiation doses that
were probably used, radiation was likely more effective on the
small cell component and less effective on the non–small cell com-
ponent.What percentage of these patients hadmixed histology, and
how accurate was your histologic evaluation for these patients?
DrDeCamp.Well, anybody who has worked with SEER or any
other database knows that they really want discrete fields. So pa-
tients whowere enteredwere forced to be diagnosedwith a discrete
classification. So within non–small cell, they can be adeno- or
squamous, but when I looked at the data fields, I didn’t see the op-
tion of mixed tumors. We went through and there are a few more
unusual forms, fusiform cell and things like that for small cell.
We eliminated the ‘‘intermediate cell’’ from our analysis because
I thought those were cases on the fence. I think your point is well
taken. Especially if it’s a needle diagnosis for small cell and the pa-
tient doesn’t respond the way you expect, I think those are likely
mixed tumors.ery c September 2011
